HCW Biologics, Inc. HCWB 深 滬
等待開盤 08-27 09:30:00 美东时间
5.89
+0.340
+6.13%
華盛通- 最 高6.01
- 今 開4.92
- 成交量 141.89万股
- 最 低 4.84
- 昨 收 5.55
- 總市值 1224.65万
- 52周最高 100.80
- 市盈率 靜 --
- 換手率 0.07%
- 52周最低 2.77
- 委 比 62.50%
- 總股本 207.92万
- 歷史最高 311.00
- 量 比 0.08
- 振 幅 21.08%
- 歷史最低 4.84
- 每 手 1
- 風險率 7.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Invivyd (NASDAQ:IVVD) stock increased by 132.3% to $1.3 during Tuesday...
08-26 20:09
HCW Biologics Stock Rockets 55% on Cancer Treatment Data
HCW Biologics stock rocketed on Monday after the company announced results from...
08-26 09:09
HCW Biologics Announces Breakthrough In Second-Generation Pembrolizumab-Based Immunotherapy For Solid Tumors, Showing Enhanced Immune Activation And Tumor Infiltration
Company's pembrolizumab-based immune checkpoint inhibitor exhibited success against solid tumors in IND-enabling studies by simultaneously activating immune cells and promoting their infiltration into solid
08-25 20:08
HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market
HCW Biologics Inc. has developed a second-generation Pembrolizumab-based immunotherapy against solid tumors, particularly pancreatic and ovarian cancer, using its TRBC platform. This therapy not only neutralizes TGF-β in the tumor microenvironment but also activates and promotes immune cell infiltration into tumors. Preclinical studies show it outperforms Pembrolizumab alone, with promising anti-tumor activity. Dr. Hing C. Wong will present these...
08-25 12:00
HCW Biologics Faces Nasdaq Non-Compliance Notice
HCW Biologics ( ($HCWB) ) has provided an announcement. On June 26, 2025, HCW B...
08-20 05:30
HCW Biologics GAAP EPS of -$16.16
HCW Biologics press release (NASDAQ:HCWB): Q2 GAAP EPS of -$16.16. Revenues for the second quarters ended June 30, 2025, and 2024 were $6,550 and $618,854, respectively. More on HCW Biologics Seeking ...
08-20 02:02
HCW Biologics Q2 EPS $(6.79) Misses $1.80 Estimate, Sales $6.550K Miss $7.000M Estimate
HCW Biologics (NASDAQ:HCWB) reported quarterly losses of $(6.79) per share which missed the analyst consensus estimate of $1.80 by 477.22 percent. This is a 57.98 percent increase over losses of $(16.16) per share from
08-19 02:46
HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results
HCW Biologics Inc. reported its second-quarter 2025 financial results and highlights, including a successful $5 million equity offering to fund Phase 1 clinical trials for HCW9302 in autoimmune diseases. The company also updated on business developments, such as extending a licensing fee payment deadline and suspending a license agreement to explore alternative partnerships. Notably, the company strengthened its balance sheet by extinguishing $7....
08-18 18:44
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers DIH Holding US (NASDAQ:DHAI) shares rose 35.1% to $0.34 during Friday'...
07-19 05:06
